Googles Shweta Maniar writes about what shes learned traveling to conferences across the planet to talk about the convergence ...

Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

Catalyst Flex, a functional service provider (FSP) solution of Catalyst Clinical Research, is a multi-therapeutic niche contract research organization (CRO)with flexible, fit-for-purpose offerings in ...

Equipped with the knowledge that the payer community has heavily restricted access to amyloid directed antibodies, Biogen and Eisai have elected to employ a very different strategy for Leqembi.

Here are three ways that the industry can evolve to support current women in STEM and open the door for a new generation of scientists.

How long should a new drug be protected against lower- cost generic or biosimilar competitors? Established patent law provides an answer, and mechanisms exist in the U.S. to challenge patents believed ...

Pharmaceutical companies should prioritize gaining control over the talent management process in order to build a robust candidate pipeline. Here are four effective strategies for recruiting, training ...

With the enthusiasm surrounding innovative product types and therapeutic approaches — and the corresponding rush to bring these new products to market — company leaders should double down on internal ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver products that improve upon currently available treatments for obesity.

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.